Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Eagle Pharmaceuticals stock

Learn how to easily invest in Eagle Pharmaceuticals stock.

Eagle Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Eagle Pharmaceuticals shares (EGRX) are listed on the NASDAQ and all prices are listed in US Dollars. Eagle Pharmaceuticals employs 102 staff and has a trailing 12-month revenue of around $272.2 million.

How to buy shares in Eagle Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EGRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Eagle Pharmaceuticals stock price (NASDAQ: EGRX)

Use our graph to track the performance of EGRX stocks over time.

Eagle Pharmaceuticals shares at a glance

Information last updated 2022-10-03.
Latest market close$24.98
52-week range$26.21 - $57.94
50-day moving average $34.46
200-day moving average $44.06
Wall St. target price$45.50
PE ratio 14.9634
Dividend yield $0 (0%)
Earnings per share (TTM) $1.64

Buy Eagle Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Eagle Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Eagle Pharmaceuticals price performance over time

Historical closes compared with the close of $24.98 from 2022-10-03

1 week (2022-09-28) -14.60%
1 month (2022-09-02) -22.52%
3 months (2022-07-05) -46.76%
6 months (2022-04-05) -48.14%
1 year (2021-10-05) -55.56%
2 years (2020-10-05) -41.73%
3 years (2019-10-04) 59.07
5 years (2017-10-05) 59.82

Is Eagle Pharmaceuticals stock undervalued or overvalued?

Valuing Eagle Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eagle Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Eagle Pharmaceuticals's P/E ratio

Eagle Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Eagle Pharmaceuticals shares trade at around 15x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Eagle Pharmaceuticals's PEG ratio

Eagle Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.91. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eagle Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Eagle Pharmaceuticals's EBITDA

Eagle Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $62.3 million.

The EBITDA is a measure of a Eagle Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Eagle Pharmaceuticals financials

Revenue TTM $272.2 million
Operating margin TTM 21.22%
Gross profit TTM $129.4 million
Return on assets TTM 11.18%
Return on equity TTM 10.53%
Profit margin 8.37%
Book value $17.93
Market capitalisation $326 million

TTM: trailing 12 months

Eagle Pharmaceuticals share dividends

We're not expecting Eagle Pharmaceuticals to pay a dividend over the next 12 months.

Eagle Pharmaceuticals share price volatility

Over the last 12 months, Eagle Pharmaceuticals's shares have ranged in value from as little as $26.21 up to $57.94. A popular way to gauge a stock's volatility is its "beta".

EGRX.US volatility(beta: 0.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eagle Pharmaceuticals's is 0.6584. This would suggest that Eagle Pharmaceuticals's shares are less volatile than average (for this exchange).

Eagle Pharmaceuticals overview

Eagle Pharmaceuticals, Inc. , a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas.

Frequently asked questions

What percentage of Eagle Pharmaceuticals is owned by insiders or institutions?
Currently 11.99% of Eagle Pharmaceuticals shares are held by insiders and 88.616% by institutions.
How many people work for Eagle Pharmaceuticals?
Latest data suggests 102 work at Eagle Pharmaceuticals.
When does the fiscal year end for Eagle Pharmaceuticals?
Eagle Pharmaceuticals's fiscal year ends in December.
Where is Eagle Pharmaceuticals based?
Eagle Pharmaceuticals's address is: 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677
What is Eagle Pharmaceuticals's ISIN number?
Eagle Pharmaceuticals's international securities identification number is: US2697961082
What is Eagle Pharmaceuticals's CUSIP number?
Eagle Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 269796108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site